Seeking Alpha

Since I wrote last summer that Enzo Biochem (ENZ) made an attractive investment opportunity in light of recent M&A in the space, the stock is up 35%, respectable, but not what I had in mind.

Since then, the company has reported four quarters of results. While the clinical lab business, which I called out as their most attractive asset, has performed alright, the products business has declined in every consecutive quarter.

Starting with the clinical lab, sales in 3 of the past 4 quarters have been encouraging. In the latest quarter reported, the company's results suffered from the effects of Hurricane Sandy, however, even excluding the hurricane, it appears revenues would have declined slightly...

Only subscribers can access this article, which is part of the PRO research library covering 3,754 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: